Research and Development
Grünbiotics bases the development of its Medical Nutrition products on solid research, clinical evidence and scientific data. We place great value on this due to the opportunity it provides our products to improve people’s lives.
Driven by evidence-based product development, Grünbiotics employs strong research partnerships and collaboration with top-tier research institutes and pharmaceutical companies. Our current R&D efforts have also steered the development of a range of products for other medical conditions (currently in the pipeline).
Grünbiotics’ research has led to the successful development of Medical Foods that address significant nutritional deficiencies and metabolic abnormalities.
Our focus is on products categorised as “Food for Special Medical Purpose” (Codex Alimentarius Commission – FAO-WHO/UN, Australia and New Zealand, the European Union and China ), “Food for Specified Health Uses” (in Japan) and “Medical Foods” (USA).
Our focus on Medical Foods means we are able to concentrate on a particular type of product. That is, while Medical Foods and pharmaceuticals are taken by those with a serious disorder, disease or medical condition, medical foods assist those who are unable to meet specialised nutritional needs via a normal diet. On the other hand, functional foods and dietary supplements are designed for healthy people to maintain their well-being.
Grünbiotics as a Social Purpose Business
Grünbiotics is driven by the fact our products provide substantial benefit to large populations worldwide; while, as a business, we remain commercially focused and profitable. In this respect, we view Grünbiotics as a social purpose business – one that uses “entrepreneurial principles to organise, mobilise and manage a for-profit business that has a social mission at its core and the goals of creating both economic and social value” (Futurpreneur Canada and Trico Charitable Foundation).
Evidence-Based Product Development
At Grünbiotics, one of our key strengths is evidence-based product development – critical to providing maximum benefits to both society and our commercial business.
In collaboration with our R&D partners, Grünbiotics’ products have been taken through robust clinical trials in line with international standards and legislation. Our research has provided well documented and scientifically proven data to back up our products.
Since establishment, Grünbiotics’ commitment to providing quality Medical Nutrition products has been demonstrated in its research spending. We have invested substantially in R&D over the years in order to provide product excellence. From a business perspective, we know that R&D spend is a major contributor and foundation of successful growth, a healthy Innovation Strategy and maximisation of benefits to society.
Our R&D Partnerships
Our R&D partnerships with top research organisations and pharmaceutical companies mean we’ve developed quality medical nutrition products that are recommended by medical professionals within the medical and healthcare arenas. This has been particularly evidenced in Grünbiotics’ successful rollout of its first product – Neurofolin® – which supports those living with depression.
Grünbiotics has teamed up with best-in-class when it comes to R&D. Our partners – both in Australia and internationally – possess state-of-the-art research facilities and labs. They also include leading research academics.
Some of our partners include researchers from:
Grünbiotics has an exclusive relationship with Merck KGaA. A science and technology company, Merck KGaA has a long history of developing products and services in the areas of Healthcare, Life Science and Performance Materials. Today, Merck KGaA has 53,000 employees in 66 countries. Grünbiotics has teamed up with Merck KGaA on both its Neurofolin® and Mild Cognitive Impairment / Alzheimer’s Dementia products.
The Florey Institute of Neuroscience and Mental Health (Melbourne, Victoria)
The Florey is a global leader in neuroscience and mental health research, focusing on stroke, epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington’s disease, motor neurone disease, traumatic brain and spinal cord injury, depression, schizophrenia, mental illness and addiction. It is the largest brain research group in the Southern Hemisphere and regarded as one of the top brain research centres in the world.
A strong research focus that has produced outstanding inventions (e.g. bionic eye), Monash is a member of the prestigious Group of Eight (Go8) and has ranked in the top one per cent of world universities (Times Higher Education World University Rankings 2017–2018), in the top 100 world universities (Academic Ranking of World Universities 2016) and 21st in the World’s Most International Universities in 2017 (Times Higher Education).
Oxford University (UK)
Grünbiotics collaborated with a number of research academics during the R&D phase of a newly developed product for Mild Cognitive Impairment / Alzheimer’s Dementia. A leader in pioneering research and innovation, in 2018 Oxford received the top ranking by The Times Higher Education World University Rankings.
Grünbiotics is set to expand their range of indications. These patent-pending applications are in the areas of:
- Mild Cognitive Impairment
- Alzheimer's Dementia
- Diabetic Peripherial Neuropathy